---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-157728"
form_type: "8-K"
ticker: "SLNO"
cik: "0001484565"
company_name: "SOLENO THERAPEUTICS INC"
filed_at: "2025-07-11T23:59:59+00:00"
generated_at: "2026-05-18T06:54:24.115904+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Soleno prices $200M public offering of 2.35M shares at $85/share for VYKAT XR commercialization

## Summary
- Priced 2,352,941 shares at $85.00/share; gross proceeds ~$200M before underwriting discounts.
- Underwriters have 30-day option to purchase up to an additional 352,941 shares at same price.
- Proceeds to fund commercialization of VYKAT XR (diazoxide choline) for Prader-Willi syndrome, approved March 26, 2025.
- Also funds EU regulatory/market development, R&D, and general corporate purposes.
- Offering expected to close July 11, 2025; joint book-runners: Goldman Sachs, Guggenheim, TD Cowen, Cantor, Oppenheimer.

## SEC filing metadata
- accession: 0001193125-25-157728
- form_type: 8-K
- ticker: SLNO
- cik: 0001484565
- company_name: SOLENO THERAPEUTICS INC
- filed_at: 2025-07-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1484565/000119312525157728/0001193125-25-157728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1484565/000119312525157728/d52794d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-157728
- JSON: https://secwatch.observer/filing/0001193125-25-157728.json
- Plain text: https://secwatch.observer/filing/0001193125-25-157728.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.